{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-306251","form_type":"8-K/A","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2026-07-16T21:20:16+00:00","discovered_at":"2026-07-16T21:22:00.246213+00:00","generated_at":"2026-07-16T21:22:05.282506+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silence Therapeutics discloses separation agreement with former executive Craig Tooman","bullets":["Salary continuation of $655,000 for 12 months plus lump sum cash severance of $250,000.","Bonus payment of $283,746.03 and healthcare premium reimbursement of $46,896.48.","Extended option exercise period: 24 months for 2023 Plan options, 12 months for 2018 Plan options.","Acceleration of unvested options upon change of control within 12 months post-separation.","Confidentiality, non-disparagement, non-solicitation covenants and release of claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-306251","json":"https://secwatch.observer/filing/0001193125-26-306251.json","markdown":"https://secwatch.observer/filing/0001193125-26-306251.md","text":"https://secwatch.observer/filing/0001193125-26-306251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/0001193125-26-306251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/sln-20260710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T21:22:05.282506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49b33c4c96","claim":"Craig Tooman resigned as other_named_officer at Silence Therapeutics plc.","evidence_excerpt":"As reported in the Original Form 8-K, effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/0001193125-26-306251-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}